SCHEMBL1581684

SCHEMBL1581684

O=S(=O)(CCCOCc1ccccc1)c1ccc(C2(CO)CC2C2CCCC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 1/20 0.37
▸ EPHX2 P34913 2/20 0.36
▸ LMNA P02545 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ GBA1 P04062 2/20 0.32
▸ UGCG Q16739 2/20 0.32
▸ GBA2 Q9HCG7 2/20 0.32
▸ FKBP1A P62942 2/20 0.32
▸ RORC P51449 4/20 0.32
▸ PKM P14618 2/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ MMP1 P03956 1/20 0.31
▸ MMP3 P08254 1/20 0.31
▸ MMP8 P22894 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1582101 0.77 GCK (0.35) HTR7ALDH1A1POLBRAB9ARORC
SCHEMBL2662191 0.74 HTR7 (0.37) HTR7EPHX2LMNAALDH1A1HTT
SCHEMBL1581715 0.73 GCK (0.45) EPHX2KMT2A
SCHEMBL1581903 0.72 GCK (0.47) EPHX2KMT2A
SCHEMBL1582252 0.71 TSHR (0.36) HTR7EPHX2LMNAALDH1A1HTT
SCHEMBL1582250 0.71 TSHR (0.36) HTR7EPHX2LMNAALDH1A1HTT
SCHEMBL1581966 0.70 CA2 (0.43) HTR7ALDH1A1POLBRAB9AKMT2A
SCHEMBL14744152 0.70 LMNA (0.46) LMNAALDH1A1HTTRORCMMP1
SCHEMBL1582098 0.69 GCK (0.36) ALDH1A1HTTPOLBMMP1MMP3
SCHEMBL1581826 0.69 GCK (0.38) LMNAALDH1A1HTTKMT2AMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 — — EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 — — US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 — — US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 HTR7 2079/4885EPHX2 3898/4885LMNA 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback